Xinpeng L.

Doctor at MOH Holdings

Singapore

About

Experience

  • Doctor at MOH Holdings Pte Ltd (Singapore)
    Jun 2023 - Present · 3 yrs 1 mo

  • A*STAR - Agency for Science, Technology and Research (4 yrs)
    • Duke-NUS Medicine: Scholarly Development Project
      Sep 2019 - Oct 2022 · 3 yrs 2 mos

      Utilize SAS software to identify novel post-prandial metabolic traits used to triage asymptomatic subjects into those with and without subclinical atherosclerosis in an Asian population at low risk of coronary heart disease.

    • Research Officer
      Nov 2018 - Aug 2019 · 10 mos

      Conducted the ARROW (identificAtion of postpRandial biomaRkers tOWards cardiovascular prevention) clinical study in partnership with Nestlé Institute of Health Sciences and the National Heart Center of Singapore. Examined an array of postprandial biomarkers such as hormones, glucose levels, inflammatory markers and metabolic flexibility indices. Acquired knowledge on safety standards and documentation requirements of human research activities in accordance with GCP and Research Governance. Completion of medical notes, case record forms (CRF's) and liaised closely with clinicians and clinical research monitors to ensure compliance with CIRB policies on data collection and security. Involved in coordinating study visits with subjects, ensuring subject compliance to trial protocol, and managing adverse events on site. Certifications: - Certificate, Intravenous Cannulation Procedure for Research Staff awarded by the Metabolic Clinical Phenotyping Unit, Department of Medicine, National University of Singapore (2019) - Singapore Good Clinical Practice (SGGCP) Certification awarded by the National Healthcare Group Singapore (2019) - Collaborative Institutional Training Initiative (CITI) program (Human Subjects Research & Responsible Conduct of Research) Certification awarded by the University of Miami (2019)

  • Masters of Science (Research) at NTU School of Biological Sciences Club
    Aug 2017 - Aug 2018 · 1 yr 1 mo

    Utilise CRISPR-dCas9 genome-editing techniques in combination with bioinformatic tools to understand leukemia and lung cancer epigenome. Epigenetically target drug resistance genes for silencing in chemo-resistant lung cancer models. Techniques employed include Python programming, mammalian cell culture, stable transfection, cell viability assays, modern CRISPR constructs molecular cloning, PCR and DNA sequencing analysis.

  • Biomedical Research Intern at Lee Kong Chian School of Medicine
    Sep 2016 - Aug 2017 · 1 yr

    Screened antimicrobial peptides for cytotoxic and immunogenic effects in different cell types and models. Honours thesis focused on examining the role of DEAD-box family protein DDX3 in T-lymphocyte migration and potential involvement in the survival of hematolymphoid cells to cause malignancies through siRNA mediated knockdown. Techniques employed include mammalian cell culture, transient transfection, cell viability assays, 2D & 3D cell migration assays, immunological assays, western blotting, flow cytometry, immunofluorescence staining, high content microscopy analysis and confocal microscopy.

  • Undergraduate Research Intern at Duke-NUS Medical School
    Jun 2016 - Aug 2016 · 3 mos

    Utilized the drosophila melanogaster model to analyse stem cell derived tumorigenesis in type I and II neuroblast lineage. Examined role of gene T63A/E, which is responsible for phosphatidylinositol transfer protein Vibrator, in regulating asymmetric cell division mediated tumourigenesis. Techniques employed include micro-dissections, generation and analysis of transgenic flies, bacterial cloning, immunofluorescence staining and confocal microscopy.